Shares of other companies:
April 24, 2024 Google’s Third Cookie Phaseout Delay Amid Regulatory Hurdles
April 19, 2024 Bitcoin Halving: Catalyst for New Price Heights?
April 18, 2024 EU Moves Toward Single Capital Market Union
Amazon: The Margin Train Is Gaining Speed
April 24, 2024
Amazon Web Services Expands Bedrock GenAI Service
April 23, 2024
Why Microsoft Stands Out As A Pre-Earnings Buy
April 23, 2024
Wall Street Lunch: Big Tech Bearishness?
April 22, 2024
April 23, 2024 Maximizing Profits: When is the Right Time to Sell Your Business?
Selling a business can be a momentous decision filled with many considerations and uncertainties. As an entrepreneur, this also symbolizes your years of…
April 12, 2024 Improve Your Financial Status: A How-To Guide
Navigating through the complexities of personal finance can often feel like walking through a maze blindfolded. This guide is crafted especially for you,…
April 12, 2024 How ZIM Integrated Container Tracking is Revolutionizing Global Trade
Have you ever wondered how your online shopping packages get to you? A big part of the answer is ZIM Integrated Container Tracking.…
March 15, 2024 6 Best Growth Stocks To Buy Now According to Metatrader 5
One of the reasons investors prefer growth stocks is that they are expected to perform better than other companies in terms of sales…
ALLO Stock News and Mentions of Allogene Therapeutics, Inc. Stocktwits
Updated: April 25, 2024 (13:15)
Sector: Healthcare
Welcome to PandaPulse, innovative analytical stock market observer, where the latest news and stocktwits meets in-depth investor relations insights. Dive into our real-time sentiment analysis to gauge the mood of the markets and arm yourself with key information that resonates with both savvy investors and casual traders.
We meticulously analyze the sentiment trend in each article for the last 60 days where Allogene Therapeutics Company is mentioned. We assess its relevance and importance to carry out an overall sentiment valuation of Allogene Therapeutics, Inc. (ALLO).
You can view the trend designation for each individual article below. We use this data to compile indicators into one comprehensive sentiment value, which represents the current information agenda about the Allogene Therapeutics stocks.
Please wait, while the data is preparing...
General evaluation of the current information agenda's sentiments
Agenda Trend
Analyzed articles
News and Mentions of Allogene Therapeutics, Inc. (ALLO)
April 24, 2024 (14:01) / "Zacks Commentary" (by Zacks Equity Research)
Allogene Therapeutics ( ALLO ) Expected to Beat Earnings Estimates: Should You Buy?
Allogene Therapeutics (ALLO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
In Article Trend: Neutral
April 8, 2024 (12:46) / "Zacks Commentary" (by Zacks Equity Research)
How Allogene ( ALLO ) Stock Stands Out in a Strong Industry
Allogene (ALLO) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
In Article Trend: Bullish
March 15, 2024 (13:32) / "Zacks Commentary" (by Zacks Equity Research)
Allogene's ( ALLO ) Q4 Loss Narrower Than Expected, Sales Miss
Allogene's (ALLO) fourth-quarter earnings beat estimates, but sales miss the mark. Management expects operating expenses for 2024 to be around $280 million.
In Article Trend: Neutral
March 14, 2024 (21:15) / "Zacks Commentary" (by Zacks Equity Research)
Allogene Therapeutics ( ALLO ) Reports Q4 Loss, Lags Revenue Estimates
Allogene Therapeutics (ALLO) delivered earnings and revenue surprises of 8.51% and 54.35%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
March 13, 2024 (16:15) / "Zacks Commentary" (by Zacks Equity Research)
Allogene ( ALLO ) Inks Deal With Arbor Bio for CRISPR Technology
Allogene (ALLO) intends to combine its next generation AlloCAR T platform with Arbor Biotechnologies' proprietary CRISPR gene therapy technology to develop therapies for autoimmune diseases.
In Article Trend: Neutral
March 13, 2024 (13:30) / "Zacks Commentary" (by Zacks Equity Research)
Clene Inc. ( CLNN ) Reports Q4 Loss, Tops Revenue Estimates
Clene Inc. (CLNN) delivered earnings and revenue surprises of 14.29% and 21.43%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
In Article Trend: Neutral
March 6, 2024 (11:55) / "Benzinga" (by Globe Newswire)
Antion Biosciences announces latest data and validation of its technology platform through important milestone achievements
In vivo Proof-of-Concept demonstrated for its off-the-shelf miCAR7 T-cell product, data presented at the 7th CAR-TCR Summit Europe Milestone achieved in its collaboration with Allogene Therapeutics
In Article Trend: Somewhat-Bullish
March 5, 2024 (14:55) / "Zacks Commentary" (by Zacks Equity Research)
Allogene Therapeutics ( ALLO ) 's Technical Outlook is Bright After Key Golden Cross
Should investors be excited or worried when a stock's 50 -day simple moving average crosses above the 200-day simple moving average?
In Article Trend: Somewhat-Bullish
February 28, 2024 (13:30) / "Benzinga" (by Globe Newswire)
Allogene Therapeutics Announces Participation in the 44th Annual TD Cowen Health Care Conference - Allogene Therapeutics ( NASDAQ:ALLO )
SOUTH SAN FRANCISCO, Calif., Feb. 28, 2024 ( GLOBE NEWSWIRE ) -- Allogene Therapeutics, Inc.
In Article Trend: Neutral
Related stocks from Healthcare sector
This website uses cookies to ensure you get the best experience on our website